Ensysce Biosciences Regains Compliance With Nasdaq
Portfolio Pulse from Benzinga Newsdesk
Ensysce Biosciences (NASDAQ:ENSC) has regained compliance with Nasdaq's Listing Rule 5550(b)(1) and will continue trading on Nasdaq's Capital Market tier.
June 13, 2023 | 8:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ensysce Biosciences has regained compliance with Nasdaq's Listing Rule 5550(b)(1), ensuring its continued trading on the Capital Market tier.
Regaining compliance with Nasdaq's Listing Rule 5550(b)(1) is a positive development for Ensysce Biosciences, as it ensures the company's continued trading on the Capital Market tier. This news may boost investor confidence and have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100